Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using a special PET scan to detect invasive fungal infections

Official title: Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions

Run by Peter MacCallum Cancer Centre, Australia · NCT06105411 · Data updated 2026-11-12

This study is testing a special PET scan with a new tracer to see if it can help find invasive fungal infections in people who have recently been diagnosed.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment10 (estimated)
SponsorPeter MacCallum Cancer Centre, Australia
Academic / other
Locations1 site (Melbourne, Victoria)
StatusRecruiting
StartedDecember 1, 2023
Main results expectedOctober 2026
Study endsApril 2027
Registry record updatedSeptember 5, 2025
Trial IDNCT06105411 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 years or older who have been diagnosed with invasive fungal infections within two weeks.

Probably not a fit

Patients who are pregnant, lactating, or have received iron infusion within one week prior to the scan may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational pilot trial aims to evaluate the effectiveness of a gallium-siderophore tracer in identifying areas of invasive Aspergillus infection in patients. It will involve 10 participants who have been diagnosed with invasive fungal infections within the last two weeks. The study will assess the localized uptake of the tracer using a 68Ga-labelled TAFC PET/CT scan, while also monitoring the safety and tolerability of this imaging technique. The trial is conducted at a single center over a period of 12-24 months.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic accuracy for invasive fungal infections, allowing for timely and appropriate treatment.

How similar studies have gone: While this approach is innovative, it is still in the proof of concept phase and has not been widely tested in similar studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient has provided written informed consent
2. Aged 18 years or older at written informed consent
3. Within 2 weeks of proven or probable or possible invasive fungal infection (IFI) diagnosis as per EORTC criteria
4. Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter
5. Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up

Exclusion Criteria:

1. Women who are pregnant or lactating.
2. Iron infusion within one week prior to scan

Where it's running

  • Peter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.